These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Formulary decision-making considerations: COX-2 inhibitors.
    Author: Shaya FT, Wong W, Shin JY, Martin L, Samant N.
    Journal: Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802.
    Abstract:
    When deciding the formulary status of a drug, Pharmacy & Therapeutics Committees must consider clinical efficacy, safety, financial implications, MCO population demographics, and other formulary options currently available. Differences in safety and effectiveness among drug classes and among drugs in the same class commonly take precedence over all other considerations, including economic ones. Particularly in light of recent events, the case of the cyclooxygenase-2 inhibitors for the treatment of arthritis yields interesting perspectives into formulary decision making.
    [Abstract] [Full Text] [Related] [New Search]